Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...

Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

Taking SGLT-2 inhibitors was associated with a 35% lower risk of developing dementia compared with taking another common diabetes drug with a different mechanism. Although the authors call for ...

namely SGLT2-inhibitors and glucagon-like peptide-1 receptor agonists. “As in the current study, the risk of developing dementia is reduced substantially (30-40 per cent). The mechanism through ...

Other studies have also shown that SGLT2 inhibitors appear to be associated with a reduced risk of dementia. “The mechanism through which these effects take place are unknown but likely relate ...

SGLT2 inhibitors on the market for HF are Eli ... In addition to Kerendia, other treatments in development that would bring a new mechanism of action to the indication include Novo Nordisk ...

Mineralys has been on the radar for some biotech investors. Read more about MLYS' hypertension treatment, upcoming trial ...

Experts compared adults on SGLT-2 drugs, which are available on the NHS ... of Oxford’s Dementia Platform UK, said: “The mechanism through which these effects take place are unknown but ...

Most recently, SGLT2 [sodium-glucose cotransporter 2] inhibitors ... It actually reduced the number of hypokalemic episodes because the mechanism of the drug is, in part, to raise potassium.

Resverlogix Corp. (TSX: RVX) (“Resverlogix” or “the Company”) today announced its presentation at the European Society of ...

On top of that, 30% of the patients were on an SGLT2 inhibitor ... As an RNA interference drug, Amvuttra may have a mechanism of action edge on tafamidis. While it reduces the circulating ...